Clinical Data Foundries: A 2030 Roadmap for Data Assetization and Modular AI in Healthcare

Clinical Data Foundries: The AI-Powered Future of Healthcare Data

Healthcare is on the brink of a transformative shift—one where clinical data, long treated as an administrative burden, is being reimagined as a dynamic, actionable asset. The rise of Clinical Data Foundries represents a paradigm change: a modular, AI-driven architecture that turns fragmented health records into a unified, interoperable resource. By 2030, these data ecosystems could redefine everything from drug discovery to personalized medicine—but the journey has already begun.

What exactly are Clinical Data Foundries? At their core, they are data assetization platforms that integrate disparate clinical, operational, and research datasets into a single, scalable infrastructure. Unlike traditional electronic health records (EHRs), which silo information, these foundries enable real-time data sharing, AI-driven analytics, and cross-organizational collaboration—all while maintaining strict privacy and compliance standards. The stakes are high: according to a 2025 McKinsey analysis, modular AI architectures could unlock trillions in value across healthcare by 2035, with Clinical Data Foundries as the backbone.

The shift is already underway. In February 2026, OneMedNet launched its Real-World Data (RWD) platform powered by Palantir Foundry, a move that signals the commercialization of this vision. Meanwhile, Microsoft’s integration of Claude in Microsoft Foundry—announced in January 2026—aims to bridge the gap between AI and medicine by enabling healthcare organizations to prepare documentation, support clinical research, and accelerate discovery without sacrificing regulatory compliance.

How Clinical Data Foundries Perform: Modular AI Architecture

Clinical Data Foundries are built on three foundational principles:

• Data Assetization: Treating clinical records as active assets rather than static archives. This involves standardizing formats (e.g., OMOP to FHIR translations), de-identifying data for secure sharing, and creating data ponds—curated repositories for specific use cases. For example, HealthLab recently de-identified 5 terabytes of clinical data for a pharmaceutical research project, enabling 6 medical publications.
• Modular AI: Deploying domain-specific AI agents (e.g., for radiology, genomics, or trial simulation) that operate on standardized data layers. Companies like SEQSTER are developing 1-click data refineries to distill raw EHR exports into structured formats, reducing AI token waste by up to 70%.
• Interoperability: Enabling seamless data flow between EHRs, wearables, and research databases. The Clinical Trials Data Network (CTDN) is a global example, transforming how trial data is registered and shared across borders.

This architecture contrasts sharply with today’s fragmented landscape, where 87% of healthcare AI projects fail due to data silos (McKinsey, 2025). Foundries address this by providing a plug-and-play environment where new AI models can be deployed without rewriting data pipelines.

Key Stakeholders and Who Stands to Gain

The impact of Clinical Data Foundries extends across the healthcare ecosystem, but the benefits—and challenges—vary by stakeholder:

For example, Arcadia Foundry simplifies healthcare data into intuitive objects, allowing analysts to query disparate sources as if they were a single database. This approach is already being adopted by 42% of top 20 pharma companies (Keyrus LifeScience, 2026), who cite faster time-to-insight as the primary driver.

Real-World Examples: Foundries in Action

While Clinical Data Foundries are still emerging, several pilots and commercial launches offer a glimpse of their potential:

• Tampa General Hospital used Palantir Foundry to create a connected health system, improving operational efficiency by 22% within 18 months (Palantir, 2023).
• Datafoundry.ai’s DF Health 4.0 platform enables end-to-end drug discovery, from clinical trial design to post-marketing surveillance, with a focus on scalable compliance (Datafoundry, 2026).
• Microsoft’s Healthcare Data Foundations provide pre-built pipelines for ingesting clinical data into lakehouses, accelerating AI model training (Microsoft Learn, 2026).

These examples highlight a critical trend: the move from point solutions (e.g., single-purpose AI tools) to modular ecosystems where data and algorithms are reusable across use cases. As Clinical Foundry CEO notes, the future isn’t about more data—it’s about smarter data infrastructure.

Challenges on the Path to Adoption

Despite the promise, several hurdles remain:

• Regulatory Uncertainty: The FDA’s Data Standards Program (updated March 2026) is evolving, but clarity on AI-driven RWE in drug approvals is still lacking.
• Data Privacy: The 92% increase in healthcare data breaches in 2025 (HHS, 2026) has heightened scrutiny over de-identification methods.
• Legacy Integration: Most hospitals run on 30+ disparate systems, making foundry adoption a multi-year IT overhaul.
• Cost: Initial setup for a Clinical Data Foundry can exceed $5–10 million, though ROI is projected within 3–5 years (McKinsey).

To address these, organizations like the Clinical Trials Data Network are advocating for pre-competitive collaboration to standardize data models and governance frameworks.

What’s Next: The 2026–2030 Roadmap

The next 12–18 months will be critical for Clinical Data Foundries. Key milestones include:

1. Q3 2026: Expected FDA guidance on AI/ML in clinical trials, likely incorporating foundry-based RWE (watch for updates).
2. 2027: Pilot programs in 5–10 major health systems (e.g., Mayo Clinic, Johns Hopkins) to test interoperability across EHR vendors.
3. 2028–2030: Widespread adoption in pharma, with 60% of top 50 companies using foundry architectures for drug development (Keyrus projection).

For readers looking to explore further, the following resources provide deeper dives:

• McKinsey’s Modular AI Framework (white paper)
• Datafoundry’s Mission Statement
• Clinical Trials Data Network (CTDN) (global collaboration)

Key Takeaways

• Clinical Data Foundries are modular AI architectures that turn clinical data into reusable assets.
• They enable real-time collaboration across hospitals, pharma, and research—reducing trial costs and improving outcomes.
• Challenges include regulation, privacy, and legacy integration, but pilots are already showing 20–50% efficiency gains.
• By 2030, foundries could become the standard infrastructure for AI-driven healthcare.

As Dr. Richard Gebler of Dresden University notes in a 2025 JMIR study, the shift from data silos to foundries is not optional—it’s the only way to scale AI responsibly in healthcare. The question is no longer if these systems will dominate, but how quickly.

What do you believe? Are Clinical Data Foundries the future, or will fragmentation persist? Share your insights in the comments—or tag us on Twitter @WorldTodayJrnl.